Current techniques rely on inefficient methods, such as limiting dilution (LD), which are time consuming, expensive, incompatible with the sensitivity of hiPSCs and ultimately, ineffective in addressing concerns about clonality.
TORONTO (PRWEB) September 09, 2020
Join Philip Manos, Founder, President & Scientific Director, EverCell Bio, Inc. and Dr. Ian Taylor, Chief Business Officer, Solentim Limited for a live webinar on Tuesday, September 22, 2020 at 11am EDT (4pm BST/UK).
Drug discovery, diagnostic and therapeutic efforts are increasingly using human-induced pluripotent stem cells (hiPSCs) and related technologies. However, the inability to robustly manipulate hiPSCs as single cells has remained a significant biological and technical hurdle. Current techniques rely on inefficient methods, such as limiting dilution (LD), which are time consuming, expensive, incompatible with the sensitivity of hiPSCs and ultimately, ineffective in addressing concerns about clonality.
In this webinar, Solentim will present a robust and clinically relevant workflow for the single-cell subcloning of hiPSCs using the VIPS seeding platform in combination with a new soluble dispensing matrix, MatriClone™(Solentim). MatriClone is an animal component-free matrix dispensed at the time of seeding, which allows for cell attachment and growth without the need for pre-coating culture plates. The VIPS instrument is uniquely able to perform the dual functions of high efficiency single-cell seeding and whole-well imaging to document outgrowth and verify clonal origin. The combination of this instrument and dispensing matrix provides a novel solution for improving workflows for cell reprogramming or gene editing of hiPSCs.
The presenters will show how numerous hiPSC cell lines can be successfully subcloned in a robust and automated fashion using the VIPS instrument in conjunction with optimized culture conditions, thereby reducing time and cost while most importantly, maintaining the integrity of clonal biology.
The robustness of this workflow has immediate potential to impact standards, consistency and confidence of clonality in both academic and pharma research. Furthermore, future translation of this workflow could positively effect GMP standards and re-establish expectations with the regulatory bodies for the development and production of advanced cell models, cellular diagnostics and cell therapeutics, including clonality documentation to accompany future IND submissions.
For more information or to register for this event, visit Establishing New Standards in Efficient Single Cell Cloning of hiPSCs.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.